Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

Safecor Health, LLC

US Class II Ongoing · initiated 2025-10-10

Labeling: Not Elsewhere Classified:Incorrect RFID tag labels applied to product by repackaging firm.

Atlantiscan

Canada Type I Archived · initiated 2025-10-10

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

Amerisource Health Services LLC

US Class II Ongoing · initiated 2025-10-09

CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that …

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

ibspot

US Class II Ongoing · initiated 2025-10-09

Marketed Without an Approved NDA/ANDA

USV Private Limited

US Class II Ongoing · initiated 2025-10-09

Failed Impurities/Degradation Specifications: The result for 'Any individual unspecified impurity' exceeds the specification limit.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-10-09

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

ASTRAZENECA PHARMACEUTICALS

US Class II Ongoing · initiated 2025-10-08

Lack of Assurance of Sterility:

Mohamed Hagar

US Class I Ongoing · initiated 2025-10-08

Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).

Sandoz Lisinopril HCT 20/25mg

Canada Type II Ongoing · initiated 2025-10-08

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…